Rhumbline Advisers lifted its holdings in BioTime, Inc. (NYSEAMERICAN:BTX) by 11.4% in the 1st quarter, HoldingsChannel reports. The firm owned 142,796 shares of the biotechnology company’s stock after purchasing an additional 14,579 shares during the quarter. Rhumbline Advisers’ holdings in BioTime were worth $187,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Defender Capital LLC. bought a new position in shares of BioTime in the fourth quarter worth $3,629,000. BlackRock Inc. grew its stake in shares of BioTime by 1.3% in the fourth quarter. BlackRock Inc. now owns 6,179,281 shares of the biotechnology company’s stock worth $5,642,000 after purchasing an additional 76,814 shares in the last quarter. Two Sigma Advisers LP grew its stake in shares of BioTime by 82.9% in the fourth quarter. Two Sigma Advisers LP now owns 154,253 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 69,900 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of BioTime by 20.0% in the third quarter. Teachers Advisors LLC now owns 185,451 shares of the biotechnology company’s stock worth $436,000 after purchasing an additional 30,916 shares in the last quarter. Finally, Creative Planning bought a new position in shares of BioTime in the first quarter worth $196,000.
Several analysts have recently weighed in on the company. Raymond James cut their price objective on BioTime from $6.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, March 18th. HC Wainwright assumed coverage on BioTime in a report on Thursday, February 21st. They issued a “buy” rating and a $4.00 price objective for the company. Maxim Group set a $3.00 price objective on BioTime and gave the company a “buy” rating in a report on Friday, February 15th. Finally, Zacks Investment Research upgraded BioTime from a “hold” rating to a “strong-buy” rating and set a $1.75 price objective for the company in a report on Tuesday, March 19th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $3.46.
BioTime (NYSEAMERICAN:BTX) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.36. The firm had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.66 million.
COPYRIGHT VIOLATION WARNING: “Rhumbline Advisers Buys 14,579 Shares of BioTime, Inc. (NYSEAMERICAN:BTX)” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://sportsperspectives.com/2019/06/14/rhumbline-advisers-buys-14579-shares-of-biotime-inc-nyseamericanbtx.html.
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
Featured Article: What is the Bid-Ask Spread?
Want to see what other hedge funds are holding BTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTime, Inc. (NYSEAMERICAN:BTX).
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.